{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:42:45Z","timestamp":1754397765410},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00277-016-2899-0","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T20:41:14Z","timestamp":1482612074000},"page":"363-371","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?"],"prefix":"10.1007","volume":"96","author":[{"given":"Etienne","family":"Paubelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Ducastelle-Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorenza","family":"Barraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wattel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"key":"2899_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.leukres.2016.05.025","volume":"47","author":"J Kell","year":"2016","unstructured":"Kell J (2016) Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. Leuk Res 47:149\u2013160","journal-title":"Leuk Res"},{"key":"2899_CR2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","volume":"88","author":"E Estey","year":"1996","unstructured":"Estey E, Kornblau S, Pierce S et al (1996) A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88:756","journal-title":"Blood"},{"key":"2899_CR3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","volume":"14","author":"EH Estey","year":"2000","unstructured":"Estey EH (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476\u2013479","journal-title":"Leukemia"},{"key":"2899_CR4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969\u20131978","journal-title":"J Clin Oncol"},{"key":"2899_CR5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2013.297","volume":"28","author":"M Fiegl","year":"2014","unstructured":"Fiegl M, Unterhalt M, Kern W et al (2014) Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia 28:1001\u20131007","journal-title":"Leukemia"},{"key":"2899_CR6","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","volume":"80","author":"JC Biggs","year":"1992","unstructured":"Biggs JC, Horowitz MM, Gale RP et al (1992) Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80:1090\u20131093","journal-title":"Blood"},{"key":"2899_CR7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","volume":"25","author":"C Craddock","year":"2011","unstructured":"Craddock C, Labopin M, Pillai S et al (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 25:808\u2013813","journal-title":"Leukemia"},{"key":"2899_CR8","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","volume":"26","author":"L Pagano","year":"2007","unstructured":"Pagano L, Fianchi L, Caira M et al (2007) The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 26:3679\u20133690","journal-title":"Oncogene"},{"key":"2899_CR9","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH Velden van Der","year":"2001","unstructured":"van Der Velden VH, te Marvelde JG, Hoogeveen PG et al (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197\u20133204","journal-title":"Blood"},{"key":"2899_CR10","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P et al (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 26:5192\u20135197","journal-title":"J Clin Oncol"},{"key":"2899_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2010.07.017","volume":"35","author":"RM Stone","year":"2011","unstructured":"Stone RM, Moser B, Sanford B et al (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: cancer and leukemia group B study 19902. Leuk Res 35:329\u2013333","journal-title":"Leuk Res"},{"key":"2899_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00277-007-0272-z","volume":"86","author":"G Specchia","year":"2007","unstructured":"Specchia G, Pastore D, Carluccio P et al (2007) Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 86:425\u2013428","journal-title":"Ann Hematol"},{"key":"2899_CR13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","volume":"50","author":"J Cortes","year":"2002","unstructured":"Cortes J, Tsimberidou AM, Alvarez R et al (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50:497\u2013500","journal-title":"Cancer Chemother Pharmacol"},{"key":"2899_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/mdm451","volume":"19","author":"L Fianchi","year":"2008","unstructured":"Fianchi L, Pagano L, Leoni F et al (2008) Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol 19:128\u2013134","journal-title":"Ann Oncol"},{"key":"2899_CR15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","volume":"45","author":"PP Piccaluga","year":"2004","unstructured":"Piccaluga PP, Martinelli G, Rondoni M et al (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 45:1791\u20131795","journal-title":"Leuk Lymphoma"},{"key":"2899_CR16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","volume":"27","author":"E Apostolidou","year":"2003","unstructured":"Apostolidou E, Cortes J, Tsimberidou A et al (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27:887\u2013891","journal-title":"Leuk Res"},{"key":"2899_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14712598.1.5.893","volume":"1","author":"EL Sievers","year":"2001","unstructured":"Sievers EL (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1:893\u2013901","journal-title":"Expert Opin Biol Ther"},{"key":"2899_CR18","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M et al (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854\u20134860","journal-title":"Blood"},{"key":"2899_CR19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986\u2013996","journal-title":"Lancet Oncol"},{"key":"2899_CR20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"AL Taksin","year":"2007","unstructured":"Taksin AL, Legrand O, Raffoux E et al (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 21:66\u201371","journal-title":"Leukemia"},{"key":"2899_CR21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379:1508\u20131516","journal-title":"Lancet"},{"key":"2899_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajh.23653","volume":"89","author":"S Pilorge","year":"2014","unstructured":"Pilorge S, Rigaudeau S, Rabian F et al (2014) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89:399\u2013403","journal-title":"Am J Hematol"},{"key":"2899_CR23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3109\/10428194.2014.986478","volume":"56","author":"SP Chantepie","year":"2015","unstructured":"Chantepie SP, Reboursiere E, Mear JB et al (2015) Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 56:2326\u20132330","journal-title":"Leuk Lymphoma"},{"key":"2899_CR24","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2013.49.0771","volume":"31","author":"S Amadori","year":"2013","unstructured":"Amadori S, Suciu S, Stasi R et al (2013) Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 31:4424\u20134430","journal-title":"J Clin Oncol"},{"key":"2899_CR25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453\u2013474","journal-title":"Blood"},{"key":"2899_CR26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bmt.2009.64","volume":"44","author":"M Lubbert","year":"2009","unstructured":"Lubbert M, Bertz H, Ruter B et al (2009) Non-intensive treatment with low-dose 5-aza-2\u2032-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML patients. Bone Marrow Transplant 44:585\u2013588","journal-title":"Bone Marrow Transplant"},{"key":"2899_CR27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.leu.2400847","volume":"11","author":"F Lacombe","year":"1997","unstructured":"Lacombe F, Durrieu F, Briais A et al (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11:1878\u20131886","journal-title":"Leukemia"},{"key":"2899_CR28","doi-asserted-by":"crossref","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV et al (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7:e51862","journal-title":"PLoS One"},{"key":"2899_CR29","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G et al (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675\u20135687","journal-title":"J Clin Oncol"},{"key":"2899_CR30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29:369\u2013377","journal-title":"J Clin Oncol"},{"key":"2899_CR31","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","volume":"30","author":"AK Burnett","year":"2012","unstructured":"Burnett AK, Russell NH, Hills RK et al (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924\u20133931","journal-title":"J Clin Oncol"},{"key":"2899_CR32","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","volume":"115","author":"B Lowenberg","year":"2010","unstructured":"Lowenberg B, Beck J, Graux C et al (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 115:2586\u20132591","journal-title":"Blood"},{"key":"2899_CR33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","volume":"101","author":"A Burnett","year":"2016","unstructured":"Burnett A, Cavenagh J, Russell N et al (2016) Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 trial. Haematologica 101:724\u2013731","journal-title":"Haematologica"},{"key":"2899_CR34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/jcm4040665","volume":"4","author":"NR Ramos","year":"2015","unstructured":"Ramos NR, Mo CC, Karp JE, Hourigan CS (2015) Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med 4:665\u2013695","journal-title":"J Clin Med"},{"key":"2899_CR35","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092\u20131099","journal-title":"Blood"},{"key":"2899_CR36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","volume":"25","author":"P Chevallier","year":"2011","unstructured":"Chevallier P, Labopin M, Turlure P et al (2011) A new leukemia prognostic scoring system for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 25:939\u2013944","journal-title":"Leukemia"},{"key":"2899_CR37","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. Blood 92:2322\u20132333","journal-title":"Blood"},{"key":"2899_CR38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D et al (2016) Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol 34:972\u2013979","journal-title":"J Clin Oncol"},{"key":"2899_CR39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00062752-199704060-00006","volume":"4","author":"MM Horowitz","year":"1997","unstructured":"Horowitz MM, Rowlings PA (1997) An update from the international bone marrow transplant registry and the autologous blood and marrow transplant registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 4:395\u2013400","journal-title":"Curr Opin Hematol"},{"key":"2899_CR40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","volume":"34","author":"JA Pollard","year":"2016","unstructured":"Pollard JA, Loken M, Gerbing RB et al (2016) CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol 34:747\u2013755","journal-title":"J Clin Oncol"},{"key":"2899_CR41","doi-asserted-by":"crossref","unstructured":"Olombel G, Guerin E, Guy J et al. (2016) The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood","DOI":"10.1182\/blood-2016-01-689976"},{"key":"2899_CR42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2016.145763","volume":"101","author":"T Witte de","year":"2016","unstructured":"de Witte T, Amadori S (2016) The optimal dosing of gemtuzumab ozagamicin: where to go from here? Haematologica 101:653\u2013654","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2899-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T06:28:36Z","timestamp":1601274516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2899-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2899"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2899-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,23]]}}}